HOME >> BIOLOGY >> NEWS
NIAMS funds the North American Spondylitis Consortium

a limited degree, antibiotics. In cases of spinal fusion, surgery is used to straighten the back and allow a person to stand upright; however, restoring original flexibility and function is not possible. There is no cure.

"Recent familial studies show genes other than HLA-B27 have possible implications for AS, " said Dr. Reveille, head of the coordinating center leading the study. "Mapping these genes may shed fundamental light on AS and other autoimmune diseases," he added. HLA-B27 is a part of a family of genes known to play a role in the function of that part of the immune system known as the major histocompatibility complex (MHC).

The consortium's goals begin with the recruitment of families in which two siblings have been diagnosed with AS. The Spondylitis Association of America will have a major role in recruitment of patients and also will maintain a central registry of information on families and sibling pairs with AS (including clinical, x-ray and laboratory data). At the University of Texas-Houston Health Science Center, researchers will establish a bank of sera (or blood), genomic DNA and frozen lymphocytes (or white blood cells) from the affected and unaffected sibling pairs, and -- when available -- both their parents.

Through genetic typing methods, researchers will search for additional alleles (or alternative forms of a gene) within the MHC that may contribute to predisposition of AS. In addition, they will conduct a genome-wide search for sibling pairs affected and unaffected by AS and map genes linked to AS that exist outside of the MHC. Finally, the research team hopes to identify, from newly mapped candidate genes, mutations and their effect on disease severity.

"We are pleased to be a part of this active ongoing partnership between an outstanding research team and the Spondylitis Association of America. This partnership is key to ensuring the success of this important project," said Dr. Katz.

The principal investig
'"/>

Contact: Kelli Carrington
carringk@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
27-Sep-1999


Page: 1 2 3

Related biology news :

1. NIAMS funds multicenter study of surgical vs. nonsurgical treatment of back pain
2. NIGMS funds Center for Quantitative Biology
3. $5 million grant funds partnership, studies of minority-based issues in reproductive health
4. NIH funds new Boston College-Boston University study of B-1a cell associated with leukemia
5. NSF funds summer research program abroad for undergraduates at UC San Diego
6. Research to create lung-cancer blood tests receives $3.4M in Pennsylvania tobacco settlement funds
7. The DFG funds a new research vessel
8. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
9. Grant funds research to develop tissue-engineered solutions for heart disease
10. Stuart research funds generating dividends for veterinary medicine
11. Grant funds research to develop microbicide barrier to HIV

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAMS funds the North American Spondylitis Consortium

(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: